Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03364153
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 12, 2018
Completion date April 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT01625559 - Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) Phase 1
Active, not recruiting NCT02749734 - Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases Phase 1/Phase 2
Completed NCT01345006 - Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy Phase 1/Phase 2
Completed NCT02445612 - Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
Completed NCT02941991 - A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Completed NCT01469832 - Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) Phase 1/Phase 2